title: Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins.
abstract: We studied the behaviour of three novel human sporadic melanoma cell lines (hmel1, hmel9, hmel11) extracted from tumors with different degrees of malignancy, concerning the cell signalling pathways controlled by MC1R, BRAF, NRAS and β-catenins. The novel cell lines were compared to metastatic cell lines (HBL, LND1), wild type (wt) for MC1R and BRAF genes, that have been extensively characterised and were used as control. All the novel cell lines have silent or no MC1R mutations even though MC1R signalling is severely impaired. Conversely, they harbour BRAF mutations at the V600 residue. These mutations determine a constitutive ERK phosphorylation in all the three cell lines. Our new melanoma cell lines were BRAF mutated in hetero- and homozygosis, even with a wild type MC1R, and unresponsive to NDP-MSH treatment. Quantity and subcellular localization of β-catenin were analyzed in both novel and control cell lines. In HBL and LND1 there were high levels of beta-catenin distributed in the cytoplasm/nucleus, while in the novel melanoma cell lines β-catenins were less abundant and seemed to be located at the plasma membrane/cytoplasm and absent in the nucleus. We sequenced beta-catenin cDNA for all the melanoma cell lines, and found mutations in HBL, LND1 and hmel1, while hmel9 and hmel11 were wt. We found that beta-catenin levels were not influenced by the RAS/RAF/MAPK pathway because inhibition with PD98059 (a MEK inhibitor) did not produce any effect on beta-catenin stability and/or localization.
authors.affiliation: Dept. of Basic Medical Sciences, University of Bari, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Zanna
authors.forename: I
authors.initials: I
authors.lastname: Maida
authors.forename: C
authors.initials: C
authors.lastname: Grieco
authors.forename: S
authors.initials: S
authors.lastname: Guida
authors.forename: M C
authors.initials: MC
authors.lastname: Turpin Sevilla
authors.forename: S
authors.initials: S
authors.lastname: De Summa
authors.forename: S
authors.initials: S
authors.lastname: Tommasi
authors.forename: G A
authors.initials: GA
authors.lastname: Vena
authors.forename: R
authors.initials: R
authors.lastname: Filotico
authors.forename: G
authors.initials: G
authors.lastname: Guida
mesh_terms: D015153:Blotting, Western; D045744:Cell Line, Tumor; D005838:Genotype; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008545:Melanoma / Q000378:metabolism* / Q000473:pathology; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D021381:Protein Transport / Q000187:drug effects; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism*; D044102:Receptor, Melanocortin, Type 1 / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013347:Subcellular Fractions / Q000187:drug effects / Q000201:enzymology; D000521:alpha-MSH / Q000031:analogs & derivatives / Q000494:pharmacology; D051176:beta Catenin / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; D044102:Receptor, Melanocortin, Type 1; D051176:beta Catenin; D000521:alpha-MSH; C027756:MSH, 4-Nle-7-Phe-alpha-; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf